Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations
NCT ID: NCT02929056
Last Updated: 2021-12-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
2 participants
INTERVENTIONAL
2017-02-15
2019-10-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be randomly assigned (like flipping a coin) into one of two treatment groups. There is an equal chance to be enrolled into either of the two treatment groups. Neither the participant nor the study doctor can control the group assignment.
Treatment Group 1: participants will receive the standard of care treatment including the use of a multi-layer compression wrap for their VLU.
Treatment Group 2: participants will receive the application of the biologic product AmnioExCel™ dressing instead of the application of an alginate dressing in addition to standard debridement and the use of a multi-layer compression wrap for their VLU. If participants have more than one VLU, only one will be enrolled in the study and will receive the application of the AmnioExCel™ dressing. The remaining VLUs will receive the application of the alginate dressing.
AmnioExCel™ is a human cellular and tissue based product that is registered with the United States Food and Drug Administration (FDA). It is intended for use as a wound covering and is made of a dehydrated human amniotic membrane (innermost layer of the placenta) that was obtained from donated human placenta. The use of AmnioExCel™ specifically for this study is not considered as standard of care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SOC alginate dressing
SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
SOC alginate dressing and compression therapy
Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
AmnioExCel dressing
AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
AmnioExCel dressing and compression therapy
Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AmnioExCel dressing and compression therapy
Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
SOC alginate dressing and compression therapy
Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At least one VLU with a total surface area between 2 cm2 and 100 cm2
3. VLU present for at least 1 month
4. Presence of a VLU extending through the full thickness of the skin but not down to muscle, tendons, or bones
5. Ulcer has a clean, granulating base with minimal adherent slough
6. VLU has been treated with compression therapy for at least 14 days
7. The study VLU has \< 30% area reduction with SOC treatment for the duration ≥ 2 weeks screening period
8. At least one of the following within the last 6 months:
* An Ankle-Brachial Index (ABI) of \> 0.75
* Dorsalis Pedis (DP) systolic pressure ≥ 80 mm Hg for diabetic patients or ≥ 60 mm Hg for non-diabetic patients on study limb
* Posterior Tibial (PT) systolic pressure ≥ 80 mm Hg for diabetic patients or ≥ 60 mm Hg for non-diabetic patients on study limb
* Great toe systolic pressure ≥ 40 mm Hg
9. Willingness to comply with the protocol, attend all follow-up visits, complete all protocol related assessments and provide informed consent
Exclusion Criteria
2. Ulcer caused by a medical condition other than venous insufficiency
3. Ulcer suspicious for cancer
4. Known history of AIDS or HIV
5. Previously treated with tissue engineered materials (e.g., Apligraft, Dermagraft or EpiFix) or other scaffold materials (e.g., Oasis or Puraply) in the past three months on the target VLU.
6. Receipt of a biologic agent, growth factor or skin substitute within the prior 30 days
7. Known sensitivity to ethanol
8. Uncontrolled diabetes mellitus with a HgBA1c of \> 10% within the past 3 months
9. Rheumatoid arthritis
10. Significant lower extremity arterial occlusive disease that would preclude the use of compression therapy
11. NYHA Class III and IV congestive heart failure (CHF)
12. Ulcers on the dorsum of the foot or with more than 50% of the ulcer below the malleolus
13. Currently receiving radiation therapy or chemotherapy
14. Receiving immune modulators
15. Currently pregnant or trying to get pregnant
16. Breast feeding
17. Not willing to provide written informed consent or remain in compliance with the study protocol requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clemson University
OTHER
BioDlogics
INDUSTRY
Prisma Health-Upstate
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Oliver, MD
Role: PRINCIPAL_INVESTIGATOR
Prisma Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Greenville Health System
Greenville, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00059274
Identifier Type: -
Identifier Source: org_study_id